Relmada Therapeutics Inc
RLMD
Get informed when a big investor buys or sells
+ FollowMarket Cap$485.64M
Close$
$0.09
98.2% downside
Current Fair Value
98.2% downsideOvervalued by 98.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $485.64 Million |
|---|---|
| Enterprise Value | $474.31 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 0.49 |
| Outstanding Shares | 112,375,941 |
Return
| Return on Equity | -29.98% |
|---|---|
| Return on Assets | -28.27% |
| Return on Invested Capital | -29.90% |
Valuation & Multiples
| P/E Ratio | -5.03 |
|---|---|
| PEG | -16.29 |
| Price to Sales | - |
| Price to Book Ratio | 4.85 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.5 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 13.71% |
|---|---|
| Total Calls | 212,200▼ 37.83% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 116.50%▲ 18.67% |
|---|---|
| Total Invested | $698.15M▲ 18.56% |
| Investors Holding | 129▲ 21.00% |
ESG Score
No data
About Relmada Therapeutics Inc
14 employees
CEO: Sergio Traversa Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed to making a difference ...